Featured Research Search Results
Metastatic Castration Resistant Prostate Cancer Clinical Trial
Clinicaltrials.gov identifier:
NCT03460977
Treatment
Treatment study for men with metastatic castration resistant prostate cancer
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04858334
Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
Clinicaltrials.gov identifier:
NCT04038502
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Advanced solid tumors
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor
Clinicaltrials.gov identifier:
NCT03607890
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Clinicaltrials.gov identifier:
NCT04042831
Treatment
Treatment study for people with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
Clinicaltrials.gov identifier:
NCT03990896
Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)
Sponsored By
